MidNite PM “Sleep Fast” And Pain Relief Claims Unsubstantiated – NAD
This article was originally published in The Tan Sheet
Meda Consumer Healthcare appeals a NAD decision to the National Advertising Review Board. Meda’s evidence failed to show whether its proprietary blend or the individual ingredients provide MidNite PM’s benefits, NAD says, and stating that each ingredient has “calming properties” is “insufficient to support the claim.”
You may also be interested in...
NAD advises Wink Naturals to discontinue online and social media claims that its melatonin-containing supplements for children are “appropriately dosed for children” and their delivery method is superior to competing products.
Hi-Tech absorbs hit from Sandy; Meda strikes MidNite deal; Sunscreen labeling due date nears; ChromaDex picks up Spherix Consulting; Chemi Pharmaceutical allegedly falsified tests; Actavis exec Boothe joins Perrigo.
Raw material supplies slowed during January-March period by catastrophic freeze in Texas and shortage of shipping containers partly due to Suez Canal blockage. "We're absorbing $90 million of incremental costs for the full year,” says CFO Ronald Dierker.